Impact of Sex on Cardiac Troponin Concentrations—A Critical Appraisal

• Published in: Clinical chemistry (Baltimore, Md.) Vol. 63; no. 9; pp. 1457 - 1464
• Main Authors: Eggers, Kai M, Lindahl, Bertil
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01.09.2017
• Subjects: Acute coronary syndromes; Angina; Atherosclerosis; Biological Assay - instrumentation; Biological Assay - standards; Biomarkers; Calcium-binding protein; Cardiology; Cardiomyocytes; Cardiovascular disease; Cardiovascular diseases; Chest; Clinical decision making; Congestive heart failure; Coronary Artery Disease - blood; Coronary vessels; Decision making; Electrocardiography; Female; Health risks; Heart; Heart attacks; Humans; Kardiologi; Male; Myocardial infarction; Pain; Patients; Population; Risk Factors; Sex; Sex Factors; Sexes; Studies; Task forces; Troponin; Troponin T - blood; Women
• ISSN: 0009-9147; 1530-8561; 1530-8561
• DOI: 10.1373/clinchem.2017.271684

The use of sex-specific cutoffs for cardiac troponin (cTn) is currently debated. Although endorsed by scientific working groups, concerns have been raised that sex-specific cutoffs may have only a small clinical effect at the cost of increased complexity in decision-making. We reviewed studies investigating the interrelations between high-sensitivity (hs) cTn results and sex, diagnoses, and outcome. Investigated populations included community-dwelling subjects and patients with stable angina, congestive heart failure, or acute chest pain including those with acute coronary syndromes. Men usually have higher hs-cTn concentrations compared with women, regardless of the assessed population or the applied assay. The distribution and prognostic implications of hs-cTn concentrations indicate that women have a broader cardiovascular risk panorama compared with men, particularly at lower hs-cTn concentrations. At higher concentrations, particularly above the 99th percentile, this variation is often attenuated. Sex-specific hs-cTn 99th percentiles have so far shown clinical net benefit in only 1 study assessing patients with chest pain. However, several methodological aspects need to be considered when interpreting study results, e.g., issues related to the determination of the 99th percentiles, the selection bias, and the lack of prospective and sufficiently powered analyses. Available studies do not show a consistent clinical superiority of sex-specific hs-cTn 99th percentiles. This may reflect methodological aspects. However, from a pathobiological perspective, the use of sex-specific hs-cTn 99th percentiles makes sense for the ruling in of myocardial infarction. We propose a new approach to hs-cTn 99th cutoffs taking into account the analytical properties of the used assays.